My recollection was that last time around MNKD was prepared to go it alone. In fact part of the FDA delaying action was the continual postponement of the FDA inspection of the manufacturing facility. Additionally I also recall a $35 million write off for a settlement of MNKD's breach of an insulin supply agreement. In my opinion Al is too smart a negotiator to let potential buyers or partners believe that MNKD isn't prepared to go forward on its own. That would only weaken MNKD' s negotiating position.